Eledon Pharmaceuticals (ELDN) EBIT (2016 - 2017)
Historic EBIT for Eledon Pharmaceuticals (ELDN) over the last 5 years, with Q1 2017 value amounting to -$3.9 million.
- Eledon Pharmaceuticals' EBIT rose 6609.76% to -$3.9 million in Q1 2017 from the same period last year, while for Mar 2017 it was -$30.5 million, marking a year-over-year increase of 2970.93%. This contributed to the annual value of -$7.5 million for FY2024, which is 6932.13% up from last year.
- Latest data reveals that Eledon Pharmaceuticals reported EBIT of -$3.9 million as of Q1 2017, which was up 6609.76% from -$3.8 million recorded in Q4 2016.
- In the past 5 years, Eledon Pharmaceuticals' EBIT registered a high of -$3.8 million during Q4 2016, and its lowest value of -$13.6 million during Q2 2016.
- Its 5-year average for EBIT is -$8.3 million, with a median of -$7.7 million in 2014.
- Its EBIT has fluctuated over the past 5 years, first plummeted by 17187.24% in 2015, then skyrocketed by 6609.76% in 2017.
- Eledon Pharmaceuticals' EBIT (Quarter) stood at -$5.5 million in 2013, then decreased by 12.83% to -$6.3 million in 2014, then tumbled by 76.84% to -$11.1 million in 2015, then surged by 66.04% to -$3.8 million in 2016, then decreased by 3.51% to -$3.9 million in 2017.
- Its EBIT stands at -$3.9 million for Q1 2017, versus -$3.8 million for Q4 2016 and -$9.3 million for Q3 2016.